Alpha-GPC (choline alphoscerate)
What it is
A choline-donating phospholipid that crosses the blood-brain barrier and serves as a precursor for the memory-related neurotransmitter acetylcholine.
What the evidence says
Evidence exists mainly in clinical, not healthy, populations. A 2023 Journal of Alzheimer's Disease systematic review and meta-analysis (8 studies, 861 participants) found alpha-GPC, alone or added to donepezil, improved cognition (MMSE/ADAS-Cog) in adults with dementia and cerebrovascular cognitive impairment. Crucially, there is essentially no good evidence it enhances cognition in healthy individuals, despite its use in nootropic and pre-workout stacks. Often dosed 400-1200 mg/day in trials.
400-1200 mg/day in clinical trials (commonly 600 mg/day); benefit in healthy users is unproven.
Educational summary of doses studied — not a recommendation. Talk to a clinician before starting any supplement.
Sources (1)
- Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis — Journal of Alzheimer's Disease (PMC10041421) (2023)
Educational summary of published research, checked against primary sources and linked inline. Not medical advice; supplements are not FDA-evaluated to treat disease. See our editorial policy.